Medical Equipment

Cancer Diagnostics Market Trends and Insights: Global Forecast to 2030

February 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the smart home market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Cancer Diagnostics Market’s size between 2026 and 2030?_x000D_

Recent years have witnessed a swift expansion in the cancer diagnostics market. Its valuation is anticipated to climb from $25.5 billion in 2025 to $28.58 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.1%. The historical drivers behind this growth include an increasing global incidence of cancer, greater investments in oncology research, the development of hospital diagnostic infrastructure, wider embrace of imaging techniques for cancer detection, and advancements in laboratory automation._x000D_

_x000D_

The cancer diagnostics market is projected to experience significant expansion over the coming years. This market is anticipated to reach $44.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. This projected growth is driven by several factors, including the rising demand for tailored cancer treatments, the increased uptake of next-generation sequencing diagnostics, the broadening of population-level cancer screening initiatives, an uptick in investments in AI-powered oncology diagnostics, and ongoing advancements in tests for detecting multiple cancers. Key developments expected during this forecast period encompass the wider acceptance of molecular and companion diagnostics, the increasing incorporation of AI in cancer detection, the expanded application of biomarker-driven testing, the proliferation of high-throughput diagnostic platforms, and a heightened emphasis on screening for early cancer._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2570&type=smp_x000D_

_x000D_

Which Drivers Are Shaping Strategic Decisions In The Cancer Diagnostics Market?_x000D_

Future expansion of the cancer diagnostics market is anticipated to be driven by increasing healthcare spending. This spending encompasses all financial outlays by governments, businesses, and individuals on medical services, such as treatments, hospital stays, medicines, and public health programs. The heightened demand for healthcare funds stems from the growing incidence of chronic illnesses, which necessitate expensive and prolonged care. Elevated healthcare spending boosts cancer diagnostics by facilitating the uptake of cutting-edge screening methods and broadening access to services for early detection. It also sharpens diagnostic precision through increased investment in contemporary equipment and dedicated laboratories, leading to prompt interventions and improved patient results. For example, data from May 2024, released by the UK’s Office for National Statistics, indicated that total healthcare spending in 2023 rose by 5.6% in nominal terms, marking a 0.9% acceleration in growth compared to 2022. Consequently, the expansion of healthcare expenditure is a key factor propelling the growth of the cancer diagnostics market._x000D_

_x000D_

What Segment Categories Are Covered In The Cancer Diagnostics Market?_x000D_

The cancer diagnostics market covered in this report is segmented – _x000D_

_x000D_

1) By Products: Companion Diagnostics, Molecular Diagnostics _x000D_

2) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging _x000D_

3) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications_x000D_

4) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users _x000D_

_x000D_

Subsegments:_x000D_

1) By Companion Diagnostics: Biomarker-Based Companion Diagnostics, Genetic Testing-Based Companion Diagnostics, Immunohistochemistry-Based Companion Diagnostics, PCR-Based Companion Diagnostics, Other Companion Diagnostics, _x000D_

2) By Molecular Diagnostics: Polymerase Chain Reaction (PCR) Diagnostics, Next-Generation Sequencing (NGS) Diagnostics, In Situ Hybridization Diagnostics, Microarray-Based Diagnostics, DNA Or RNA Extraction Kits, Other Molecular Diagnostics_x000D_

_x000D_

Which Trends Are Influencing The Development Of The Cancer Diagnostics Market?_x000D_

Leading companies in the cancer diagnostic device market are prioritizing the development of artificial intelligence (AI) technology, such as QAi Prostate, to achieve a competitive edge. QAi Prostate serves as a cancer diagnostic device specifically for prostate cancer diagnosis. For instance, in March 2023, Qritive, a Singapore-based company known for developing AI-powered diagnostic tools for pathologists, launched QAi Prostate. This tool, QAi Prostate, is an advanced artificial intelligence (AI)-powered prostate cancer diagnosis tool. It utilizes machine learning algorithms to accurately identify and classify malignant and benign areas within prostate tissue samples. The design of this tool is intended to help pathologists detect prostate cancer and distinguish between malignant and benign areas in prostate tissue samples._x000D_

_x000D_

Which Major Firms Are Strengthening Their Position In The Cancer Diagnostics Market?_x000D_

Major companies operating in the cancer diagnostics market are Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, Invitae Corporation, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics _x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report_x000D_

_x000D_

Which Region Is Anticipated To See The Fastest Growth In The Cancer Diagnostics Market?_x000D_

North America was the largest region in the cancer diagnostics market in 2025. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Cancer Diagnostics Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2570&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Cancer Diagnostics Market 2026, By The Business Research Company#_x000D_

_x000D_

Oncology Biomarkers Global Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report_x000D_

_x000D_

Clinical Biomarkers Global Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report_x000D_

_x000D_